Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women

Cancer Epidemiology Biomarkers and Prevention

Volumn 19, Issue 6, 2010, Pages 1585-1594

  Insinga, Ralph P ^a   Perez, Gonzalo ^a,b   Wheeler, Cosette M ^c   Koutsky, Laura A ^d   Garland, Suzanne M ^e   Leodolter, Sepp ^f   Joura, Elmar A ^f   Ferris, Daron G ^g   Steben, Marc ^h   Brown, Darron R ⁱ   Elbasha, Elamin H ^a   Paavonen, Jorma ^j   Haupt, Richard M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSIDAD DEL ROSARIO   (Colombia)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e ROYAL WOMEN'S HOSPITAL   (Australia)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g MEDICAL COLLEGE OF GEORGIA   (United States)

^h INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

ⁱ INDIANA UNIVERSITY   (United States)

^j HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DISEASE CLASSIFICATION; DISEASE DURATION; FEMALE; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UTERINE CERVIX; DOUBLE BLIND PROCEDURE; GENETICS; ISOLATION AND PURIFICATION; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); UTERINE CERVICAL DISEASES; VIROLOGY; YOUNG ADULT;

VIRUS DNA;

ADOLESCENT; CLINICAL TRIALS, PHASE III AS TOPIC; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INCIDENCE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UTERINE CERVICAL DISEASES; YOUNG ADULT;

EID: 77953297415     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-1235     Document Type: Article

References (34)

1. Castellsague X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 2008;110:S4-7.
2. Giuliano AR, Tortolero-Luna G, Ferrer E, et al. Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008;26 Suppl 10:K17-28.
3. Wiley D, Masongsong E. Human papillomavirus: the burden of infection. Obstet Gynecol Surv 2006;61:S3-14.
4. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009;124:1626-36.
5. Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008;17:1611-22.
6. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85.
7. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009;199:926-35.
8. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4. 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
9. Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009;199:936-44.
10. Stanley M, Gissmann L, Nardelli-Haefliger D. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines. Vaccine 2008;26 Suppl 10:K62-7.
11. Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev 2007;16:709-15.
12. Goodman MT, Shvetsov YB, McDuffie K, et al. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res 2008;68:8813-24.
13. Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004;190:2077-87.
14. Richardson H, Kelsall G, Tellier P, et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 2003;12:485-90.
15. Trottier H, Mahmud S, Prado JC, et al. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis 2008;197:1436-47.
16. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831-6.
17. Kim JJ, Brisson M, Edmunds WJ, Goldie SJ. Modeling cervical cancer prevention in developed countries. Vaccine 2008;26 Suppl 10:K76-86.
18. Garland SM, Steben M, Hernandez-Avila M, et al. Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines. Clin Vaccine Immunol 2007;14:792-5.
19. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
20. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18-27. (Pubitemid 43755499)
21. International patent numbers WO 2003/019143 A2, WO 2006/116276 A2, and WO 2006/116303 A2. Available at: http://www.wipo.int/-portal/index.html.en. Accessed 23 June 2009.
22. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994;169:235-40.
23. Xi LF, Carter JJ, Galloway DA, et al. Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. Cancer Epidemiol Biomarkers Prev 2002;11:343-51.
24. Canadas MP, Bosch FX, Junquera ML, et al. Concordance of prevalence of human papillomavirus DNA in anogenital and oral infections in a high-risk population. J Clin Microbiol 2004;42:1330-2.
25. Roberts CC, Liaw KL, Skjeldestad FE, Jansen KU, Bryan JT. Importance of specimen type in detecting human papillomavirus DNA from the female genital tract. J Med Virol 2009;81:1620-6.
26. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Koutsky LA. Comparison of incident cervical and vulvar/vaginal human papillomavirus infections in newly sexually active young women. J Infect Dis 2009;199:815-8.
27. Holmes J, Hemmett L, Garfield S. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies. Eur J Health Econ 2005;6:30-7.
28. Giuliano AR, Harris R, Sedjo RL, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. J Infect Dis 2002;186:462-9.
29. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218-26.
30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
31. Allison PD. Survival Analysis Using SAS: A Practical Guide. Cary (NC): SAS Press; 1995.
32. Cox DR. Regression models and life tables (with discussion). J R Stat Soc 1972;B34:187-220.
33. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989;84:1074-9.
34. Sycuro LK, Xi LF, Hughes JP, et al. Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis 2008;198:971-8.